Tag
This article reviews a 13-year longitudinal study assessing blood-based biomarkers’ effectiveness in predicting all-cause dementia among community-dwelling older adults, highlighting their modest sensitivity and enhanced predictive value wh
This study reveals that midlife plasma p-tau181 predicts faster memory decline over 11 years, highlighting a long prodromal phase of Alzheimer’s disease. Late-life biomarkers p-tau181, NfL, and GFAP correlate with accelerated cognitive decl
Early disclosure of plasma p-tau217 and NfL biomarkers significantly improves diagnostic confidence and clinical decisions in cognitive decline without increasing emotional distress, supporting their integration into routine memory clinic c
This review examines the impact of traumatic brain injury on the accuracy of Alzheimer disease blood biomarkers, highlighting reduced diagnostic performance in TBI-affected populations and the implications for clinical interpretation.
This article reviews a systematic meta-analysis of 15 cerebrospinal fluid and blood biomarkers for Alzheimer’s disease, highlighting robust diagnostic performance of core markers T-tau, P-tau, and Aβ42 in clinical practice and researc
Kidney function influences certain Alzheimer’s disease blood biomarker levels but, within normal to mild impairment ranges, does not improve prediction of amyloid-β positivity, supporting the clinical utility of blood biomarkers in AD
This cohort study from the Young Finns Study elucidates factors influencing blood-based biomarkers for neurodegenerative diseases, highlighting age, APOE ε4 genotype, kidney function, metabolic parameters, and notable intergenerational asso
